Identification of glutathione transferase (GST P1) inhibitors via a high-throughput screening assay and implications as alternative treatment options for breast cancers
PLOS One · 24.07.2025 · 20 (7) · e0319904
DOI: 10.1371/journal.pone.0319904 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 24.07.2025. Verfasst von Sarah A P Pereira und 5 weiteren Autor:innen. Beteiligte Einrichtung: LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, Porto, Portugal. Hauptthemen laut MEDLINE: Breast Neoplasms, High-Throughput Screening Assays, Glutathione S-Transferase pi, Enzyme Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Fundação para a Ciência e a Tecnologia.
Abstract (Originalsprache)
Glutathione S-transferase P1-1 (GST P1) is an important drug target as it is implicated in drug resistance. GST P1-1 inhibitors are typically non-productive analogues of glutathione which covers broad chemical space; hence it is likely that several clinically used drugs may unknowingly act as GST P1-1 inhibitors. We developed a high-throughput screening assay for GST P1-1 and screened 5830 compounds. From the screening, 24 potent GST P1-1 inhibitors were identified and assessed for cytotoxicity in MCF-7 and MDA-MB-231 breast cancer cell lines. Ethacrynic acid (a known GST P1-1 inhibitor), ZM 39923, PRT 4165, 10058-F4, and cryptotanshinone were shown to be the most active. A competitive GST P1-1 assay was performed to identify the inhibition type of these five compounds. Another in vitro cytotoxicity experiment was conducted to explore the differences in the cytotoxicity profiles of the combinations tested. Western blot analysis was used to identify the presence of GST P1-1 in the breast cancer cell lines tested. The implications of these results concerning alternative treatment options for breast cancers are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, Porto, Portugal.
- Institut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
- Biomolecular Screening Facility, École Polytechnique Federale de Lausanne (EPFL), Lausanne, Switzerland.
ORCID-Profile: Sarah A P Pereira
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Pereira, S. A. P., Vesin, J., Chambon, M., Turcatti, G., Saraiva, M. L. M. F. S., & Dyson, P. J. (2025). Identification of glutathione transferase (GST P1) inhibitors via a high-throughput screening assay and implications as alternative treatment options for breast cancers. PLOS One, 20(7), e0319904. https://doi.org/10.1371/journal.pone.0319904
Vancouver
Pereira SAP, Vesin J, Chambon M, Turcatti G, Saraiva MLMFS, Dyson PJ. Identification of glutathione transferase (GST P1) inhibitors via a high-throughput screening assay and implications as alternative treatment options for breast cancers. PLOS One. 2025;20(7):e0319904. doi:10.1371/journal.pone.0319904
BibTeX
@article{Pereira2025,
author = {Pereira, Sarah A P and Vesin, Jonathan and Chambon, Marc and Turcatti, Gerardo and Saraiva, M Lúcia M F S and Dyson, Paul J},
title = {Identification of glutathione transferase (GST P1) inhibitors via a high-throughput screening assay and implications as alternative treatment options for breast cancers},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {7},
pages = {e0319904},
doi = {10.1371/journal.pone.0319904}
}
EUVIMED